Company Long-Term Loans and Borrowings: Crinetics Pharma (CRNX)

Public company logo of Crinetics Pharma (CRNX)

Development risks for oral treatments for hormonal imbalances impact the amount of long-term financial debt for Crinetics Pharmaceuticals (CRNX), where the current figure is 0.04. Stability is supported by sustainable drug synthesis methods aimed at waste reduction. The strategy is based on organic portfolio growth and independent product launches without the involvement of external partners.

CRNX Crinetics Pharmaceuticals Company Long-Term Debts (07/04/2022 - 09/12/2026)

Summary analytical data breakdowns for Crinetics Pharma (CRNX)

- market price and analyst price targets:
Stock Price crinetics.com|CRNX - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Crinetics|CRNX - Total Company Value
- book capitalization information:
Accounting Value per Share Crinetics|CRNX - Book Capitalization|Market Capitalization to Book Value Ratio crinetics.com|CRNX - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Crinetics Pharmaceuticals|CRNX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Crinetics Corp|CRNX - Company Aggregate Debts|Debts to Book Value Crinetics|CRNX - Company Long-Term Liabilities|Amount of Current Liabilities Crinetics|Quick Ratio crinetics.com
- earnings and multiples data:
CRNX - Net Profit
Summary company analytics:Crinetics Pharmaceuticals
Brand item of Crinetics Pharmaceuticals

This indicator captures the total volume of credit obligations with a maturity of more than one year, determining long-term financial stability and the cost of capital servicing. By analyzing the magnitude of the issuer's long-term liabilities, an investor assesses the ability of Crinetics Pharmaceuticals (CRNX) to fund costly endocrine drug development and laboratory maintenance under strict FDA regulations without risking a loss of operating margins.

Competitor analysis for Crinetics Pharmaceuticals

Company Long-Term Debts ascendispharma.com ASND|MDGL - Company Long-Term Debt|Company Long-Term Loans and Borrowings CORT (Corcept Therapeutics Inc.)|Rhythm Pharmaceuticals Inc (RYTM) - Company Long-Term Debt|Company Long-Term Liabilities Akero Corp|MTSR (Metsera Inc) - Company Long-Term Debts|Company Long-Term Debts moonlaketx.com|Company Long-Term Liabilities NAMS (NewAmsterdam Pharma Company N.V.)|SLNO (Soleno Therapeutics Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Amicus Pharma FOLD|ETNB - Company Long-Term Liabilities|Agios Pharmaceuticals - Company Long-Term Debts|Long-Term Debt structuretx.com|MDXG (MiMedx) - Company Long-Term Liabilities|RZLT: Amount of Long-Term Liabilities|LXRX (Lexicon Pharma) - Company Long-Term Debts|Company Long-Term Debts MBX Corp|Company Long-Term Debts ALT|Company Long-Term Debt AARD (aardvarktherapeutics.com)|Company Long-Term Debt Sagimet Biosciences Inc. SGMT|BioAge Labs (BIOA) - Long-Term Debt|BMEA - Company Long-Term Debt|QNCX: Company Long-Term Debt|GUTS: Company Long-Term Debts|VTVT - Long-Term Debt Volume|Company Long-Term Debt Agape ATP Corp|Pluri Inc (PLUR) - Long-Term Debt Volume|Company Long-Term Debt Synlogic, Inc. (SYBX)|Company Long-Term Liabilities Lipocine Corporation LPCN|Company Long-Term Debts MTNB (Matinas BioPharma Holdings)|SPRB - Company Long-Term Liabilities|GLTO - Company Long-Term Debt|Company Long-Term Loans and Borrowings CTCX (Carmell Corp.)|LUMO: Company Long-Term Debts|ONVO - Long-Term Debt Volume|Company Long-Term Debt Radius Recycling, Inc.